Targeting rheumatoid tenosynovial angiogenesis with cytokine inhibitors

Clinical Orthopaedics and Related Research

Volumn 446, Issue , 2006, Pages 268-277

  Jain, Abhilash ^a   Kiriakidis, Serafim ^a   Brennan, Fionula ^a   Sandison, Ann ^a   Paleolog, Ewa ^a   Nanchahal, Jagdeep ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC PROTEIN; ANGIOPOIETIN 2; COLLAGENASE 3; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANTIRHEUMATIC AGENT; CYTOKINE; INFLIXIMAB; INTERLEUKIN 1; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; HAND SURGERY; HUMAN; HUMAN TISSUE; HYPOXIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RHEUMATOID ARTHRITIS; SYNOVIUM; TENDON; TISSUE LEVEL; VASCULARIZATION; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-1; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; SYNOVIAL MEMBRANE; TENDONS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33744739442     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/01.blo.0000205909.89845.f6     Document Type: Article

References (42)

1. Afuwape AO, Kiriakidis S, Paleolog EM. The role of angiogenic molecule VEGF in the pathogenesis of rheumatoid arthritis. Histol Histopathol. 2002;17:961-972.
2. Akil M, Amos RS. ABC of rheumatology: rheumatoid arthritis - I: clinical features and diagnosis. BMJ. 1995;310:587-590.
3. Arend WP. Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. Semin Arthritis Rheum. 2001;30(5 suppl 2):1-6.
4. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
5. Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. 1995;372:83-87.
6. Berse B, Hunt JA, Diegel RJ, Morganelli P, Yeo K, Brown F, Fava RA. Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1) - induced vascular endothelial growth factor secretion by rheumatoid synovial fibroblasts. Clin Exp Immunol. 1999;115:176-182.
7. Brown FE, Brown ML. Long-term results after tenosynovectomy to treat the rheumatoid hand. J Hand Surg. 1988;13:704-708.
8. Cernanec J, Guilak F, Weinberg JB, Pisetsky DS, Fermor B. Influence of hypoxia and reoxygenation on cytokine-induced production of proinflammatory mediators in articular cartilage. Arthritis Rheum. 2002;46:968-975.
9. Engkvist O, Lundborg G. Rupture of the extensor pollicis longus tendon after fracture of the lower end of the radius: a clinical and microangiographic study. Hand. 1979;11:76-86.
10. Engelberts I, Moller A, Schoen GJM, van der Linden CJ, Buurman WA. Evaluation of human TNF in plasma by ELISA. Lymphokine Cytokine Res. 1991;10:60-76.
11. Ertel AN. Flexor tendon ruptures in rheumatoid arthritis. Hand Clin. 1989;5:177-190.
12. Ertel AN, Millender LH, Nalebuff E, McKay D, Leslie B. Flexor tendon ruptures in patients with rheumatoid arthritis. J Hand Surg. 1988;13:860-866.
13. Fearon U, Griosios K, Fraser A, Reece R, Emery P, Jones PF, Veale DJ. Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol. 2003;30:260-268.
14. Feldmann M, Maini R. Anti-TNFα therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol. 2001;19:163-196.
15. th ed. New York, NY: Churchill Livingstone; 1999:1651-1739.
16. Ferlic DC. Rheumatoid flexor tenosynovitis and rupture. Hand Clin. 1996;12:561-572.
17. Jackson JR, Minton JA, Ho ML, Jackson JR, Minton JA, Ho ML, Wei N, Winkler JD. Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta. J Rheumatol. 1997;24:1253-1259.
18. Jain A, Brennan F, Nanchahal J. Treatment of rheumatoid tenosynovitis with cytokine inhibitors. Lancet. 2002;360:1565-1566.
19. Jain A, Brennan F, Troeberg L, Nanchahal J. The role of matrix metalloproteinases in rheumatoid tendon disease. J Hand Surg. 2002;27:1059-1064.
20. Jain A, Nanchahal J, Troeberg L, Green P, Brennan F. Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinase 1 by tenosynovial lining demonstrates its potential for tendon destruction in rheumatoid arthritis. Arthritis Rheum. 2001;44:1754-1760.
21. Jones ME, Ladhani K, Mudera V, Grobbelaar AO, McGrouther DA, Sanders R. Flexor tendon blood vessels. J Hand Surg. 2000;25:552-559. [Br]
22. Kaiser MJ, Bozonnat MC, Jorgensen C, Daures JP, Sany J. Effect of etanercept on tenosynovitis and nodules in rheumatoid arthritis. Arthritis Rheum. 2002;46:559-560.
23. Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature. 1995;376:517-519.
24. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 1992;258:1798-1801.
25. Leslie BM. Rheumatoid extensor tendon ruptures. Hand Clin. 1989;5:191-202.
26. Mapp PI, Grootveld MC, Blake DR. Hypoxia, oxidative stress and rheumatoid arthritis. Br Med Bull. 1995;51:419-436.
27. Nagashima M, Asano G, Yoshino S. Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. J Rheumatol. 2000;27:2339-2342.
28. Paleolog EM. Angiogenesis in rheumatoid arthritis. Arthritis Res. 2002;4(suppl 3):s81-s90.
29. Paleolog EM, Fava RA. Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategies. Springer Semin Immunopathol. 1998;20:73-94.
30. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum. 1998;41:1258-1265.
31. Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, Koch AE. Evidence of IL-8 as a novel angiogenic mediator. J Immunol. 2001;167:1644-1653.
32. Qu Z, Huang XN, Ahmadi P, Andresevic J, Planck SR, Hart CE, Rosenbaum JT. Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis and degenerative joint disease. Lab Invest. 1995;73:339-346.
33. Roeckl W, Hecht D, Sztajer H, Waltenberger J, Yayon A, Weich HA. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. Exp Cell Res. 1998;241:161-170.
34. Scott BB, Zaratin PF, Colombo A, Hansbury MJ, Winkler JD, Jackson JR. Constitutive expression of angiopoietin-1 and -2 and modulation of their expression by inflammatory cytokines in rheumatoid arthritis synovial fibroblasts. J Rheumatol. 2002;29:230-239.
35. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct. 2001;26:25-35.
36. Shukla DD. Bilateral spontaneous rupture of achilles tendon secondary to limb ischemia: a case report. J Foot Ankle Surg. 2002;41:328-329.
37. Stevens CR, Blake DR, Merry P, Revell PA, Levick JR. A comparative study by morphometry of the microvasculature in normal and rheumatoid synovial lining. Arthritis Rheum. 1991;34:1508-1513.
38. Strunk J, Lange U, Kürten B, Schmidt KL, Neeck G. Doppler sonographic findings in the long bicipital tendon sheath in patients with rheumatoid arthritis as compared with patients with degenerative disease of the shoulder. Arthritis Rheum. 2003;48:1828-1832.
39. Ulfgren A, Andersson U, Engström M, Klareskog L, Maini RN, Taylor PC. Systemic anti-tumor necrosis factor α therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor α synthesis. Arthritis Rheum. 2000;43:2391-2396.
40. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA, Apte RN. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA. 2003;100:2645-2650.
41. Williamson SC, Feldon P. Extensor tendon ruptures in rheumatoid arthritis. Hand Clin. 1995;11:449-459.
42. Woessner JF, Nagase H. Matrix Metalloproteinases and TIMPs. Oxford, England: Oxford University Press; 2000:87-93.